CB21 Pharma, a leading Czech-based pharmaceutical company specializing in producing cannabinoid ingredients and medical devices, has successfully extended its EU Good Manufacturing Practice (GMP) certification under certificate # sukls105303/2023. This achievement allows CB21 Pharma, the spin-off sister company to pioneering CBDepot, to continue manufacturing Active Pharmaceutical Ingredients (APIs) such as Cannabidiol (CBD), from initial extraction to the production of full spectrum distilled and standardized extracts from medicinal cannabis, marketed as Cannabis Extractum Raffinatum and Cannabis Extractum Normatum.
CB21 Pharma is a pharmaceutical company that develops and markets innovative treatments for medical pathologies based on non-psychotropic cannabinoids combined with other active substances. The company also innovates, manufactures, and markets clean-label functional cosmetics for the 21st century. The extension of the EU GMP certification underscores the company’s commitment to maintaining the highest standards in its manufacturing processes and product quality.
In addition to its ongoing production, CB21 Pharma is also making strides in expanding its product portfolio. The company is diligently working towards introducing API Dronabinol to the market by the end of this year.
CB21 Pharma’s vision is to be a world leader in developing pharmaceutical products based on non-psychotropic cannabinoids, utilizing evidence-based medicine, development processes, and regulatory and manufacturing expertise. The company’s focus on patient benefit is a constant driving force of its research program and achievements. By leveraging the most up-to-date science, preclinical and clinical development, and advanced technologies, CB21 Pharma’s R&D department ensures the highest quality of new products for the end user.
“The successful extension of the EU GMP certification is a significant and awaited milestone for CB21 Pharma and its expanding customer base”, says Boris Baňas, responsible for global substance sales. “It validates the company’s adherence to international manufacturing standards and reinforces its commitment to delivering high-quality, safe, and effective cannabinoid products to the global market”, adds Mr. Baňas.
According to CEO Jan Storch, “CB21 Pharma’s accomplishments demonstrate its commitment to quality and innovation in the pharmaceutical sector. As the company continues to grow and expand its product offerings, it remains steadfast in its mission to provide the highest quality cannabinoid ingredients for pharmaceutical use. This contribution to the advancement of medical science and the improvement of patient care worldwide”.
Save the dates.
On the 17th of October, Boris Baňas and Jan Storch are hosting a webinar Czech-Made EU GMP Cannabis-Derived APIs.
Please register to learn more about the expanded portfolio of EUDRA-listed EU GMP CBD and EU GMP cannabis extracts fit for clinical trials and medicine development.
Alternatively, visit us at CPHI Barcelona 24-26th of October at our stand #80C32 and meet us in person to discuss your cannabinoid-based projects.
